This page is intended for UK health professionals only. If you are a patient / carer, please click here.
If you are a member of the general public, please click here.
Indications: Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with Von Willebrand disease, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.3
How to Reconstitute Voncento
Mix2Vial is a registered Trade Mark of West Pharmaceutical Services, Inc. or a subsidiary thereof.
References
-
Lissitchkov TJ, Buevich E, et al. Pharmacokinetics, efficacy,
and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for
on-demand and prophylactic treatment in patients with Von Willebrand disease (SWIFT-VWD study). Blood Coagulation and Fibrinolysis. 2017;28(2):152-162. - Auerswald G, Khayat CD, et al. Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVII Concentrate (Formulation V) in Pediatric Patients with Von Willebrand Disease (SWIFTLY-VWD Study). Journal of Blood Medicine. 2020;11:213-225.
- CSL Berhing UK Limited. Voncento Summary of Product Characteristics.
Reporting adverse events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple store Adverse events should also be reported to CSL Behring UK Ltd. on 01444 447 405.